Dn B Asset Management As Biogen Inc. Transaction History

Dn B Asset Management As

$19.9 Billion
Q2 2024

A detailed history of Dn B Asset Management As transactions in Biogen Inc. stock. As of the latest transaction made, Dn B Asset Management As holds 61,226 shares of BIIB stock, worth $12 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

61,226

Previous 53,253 14.97%

Holding current value

$12 Million

Previous $11.5 Million 23.61%

% of portfolio

0.07%

Previous 0.06%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 05, 2024	BUY	$190.52 - $236.72 $1.52 Million - $1.89 Million	7,973 Added 14.97%	61,226 $14.2 Million
Q1 2024 Apr 12, 2024	SELL	$212.02 - $267.71 $468,776 - $591,906	-2,211 Reduced 3.99%	53,253 $11.5 Million
Q4 2023 Jan 04, 2024	SELL	$222.59 - $267.94 $3.13 Million - $3.76 Million	-14,048 Reduced 20.21%	55,464 $14.4 Million
Q3 2023 Oct 13, 2023	BUY	$253.3 - $285.89 $1.63 Million - $1.84 Million	6,443 Added 10.22%	69,512 $17.9 Million
Q2 2023 Jul 06, 2023	BUY	$275.25 - $318.06 $1.08 Million - $1.25 Million	3,929 Added 6.64%	63,069 $18 Million
Q1 2023 Apr 20, 2023	BUY	$256.56 - $292.34 $4.22 Million - $4.81 Million	16,467 Added 38.59%	59,140 $16.4 Million
Q4 2022 Jan 12, 2023	SELL	$252.44 - $306.72 $559,659 - $679,998	-2,217 Reduced 4.94%	42,673 $11.8 Billion
Q3 2022 Oct 11, 2022	BUY	$194.69 - $268.46 $445,645 - $614,504	2,289 Added 5.37%	44,890 $12 Million
Q2 2022 Jul 08, 2022	SELL	$187.54 - $223.02 $39,946 - $47,503	-213 Reduced 0.5%	42,601 $8.69 Billion
Q1 2022 Apr 08, 2022	SELL	$193.77 - $244.14 $608,437 - $766,599	-3,140 Reduced 6.83%	42,814 $9.02 Million
Q4 2021 Jan 12, 2022	BUY	$223.92 - $287.77 $601,896 - $773,525	2,688 Added 6.21%	45,954 $11 Million
Q3 2021 Oct 15, 2021	BUY	$282.99 - $369.05 $590,883 - $770,576	2,088 Added 5.07%	43,266 $12.2 Million
Q2 2021 Jul 06, 2021	SELL	$259.0 - $414.71 $2.55 Million - $4.08 Million	-9,828 Reduced 19.27%	41,178 $14.3 Billion
Q1 2021 Apr 15, 2021	SELL	$242.95 - $284.63 $30.2 Million - $35.4 Million	-124,326 Reduced 70.91%	51,006 $14.3 Million
Q4 2020 Jan 19, 2021	SELL	$236.26 - $355.63 $16.6 Million - $25 Million	-70,392 Reduced 28.65%	175,332 $42.9 Million
Q3 2020 Oct 14, 2020	BUY	$264.77 - $305.71 $24.9 Million - $28.8 Million	94,045 Added 62.0%	245,724 $69.7 Million
Q2 2020 Jul 08, 2020	BUY	$258.66 - $342.55 $1.1 Million - $1.46 Million	4,255 Added 2.89%	151,679 $40.6 Billion
Q1 2020 Apr 17, 2020	BUY	$268.85 - $341.04 $11.4 Million - $14.5 Million	42,395 Added 40.37%	147,424 $46.6 Million
Q4 2019 Jan 13, 2020	BUY	$220.06 - $304.07 $6.33 Million - $8.75 Million	28,775 Added 37.74%	105,029 $31.2 Million
Q3 2019 Oct 16, 2019	BUY	$217.44 - $243.88 $2.81 Million - $3.15 Million	12,936 Added 20.43%	76,254 $17.8 Million
Q2 2019 Jul 08, 2019	SELL	$219.29 - $241.72 $16.2 Million - $17.8 Million	-73,702 Reduced 53.79%	63,318 $0
Q1 2019 Apr 11, 2019	BUY	$216.71 - $338.96 $7.1 Million - $11.1 Million	32,776 Added 31.44%	137,020 $0
Q4 2018 Jan 15, 2019	BUY	$278.5 - $352.75 $2.75 Million - $3.48 Million	9,878 Added 10.47%	104,244 $31.4 Million
Q3 2018 Oct 10, 2018	SELL	$293.51 - $383.83 $872,605 - $1.14 Million	-2,973 Reduced 3.05%	94,366 $0
Q2 2018 Jul 06, 2018	BUY	$257.52 - $306.91 $2.5 Million - $2.98 Million	9,700 Added 11.07%	97,339 $0
Q1 2018 Apr 11, 2018	BUY	$260.13 - $367.91 $11.6 Million - $16.4 Million	44,620 Added 103.72%	87,639 $0
Q4 2017 Jan 10, 2018	BUY	$307.64 - $344.58 $100,290 - $112,333	326 Added 0.76%	43,019 $0
Q3 2017 Oct 11, 2017	BUY	$281.15 - $329.69 $12 Million - $14.1 Million	42,693	42,693 $0

Others Institutions Holding BIIB

# of Institutions

1,050

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $28.2B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dn B Asset Management As, based on Form 13F filings with the SEC.

News

Stay updated on Dn B Asset Management As with notifications on news.

Account

Dn B Asset Management As Biogen Inc. Transaction History